1. Home
  2. VSME vs ICUCW Comparison

VSME vs ICUCW Comparison

Compare VSME & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VSME
  • ICUCW
  • Stock Information
  • Founded
  • VSME 2013
  • ICUCW N/A
  • Country
  • VSME Hong Kong
  • ICUCW United States
  • Employees
  • VSME N/A
  • ICUCW 19
  • Industry
  • VSME
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • VSME
  • ICUCW Health Care
  • Exchange
  • VSME Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • VSME N/A
  • ICUCW N/A
  • IPO Year
  • VSME 2023
  • ICUCW 2021
  • Fundamental
  • Price
  • VSME $1.10
  • ICUCW $0.03
  • Analyst Decision
  • VSME
  • ICUCW
  • Analyst Count
  • VSME 0
  • ICUCW 0
  • Target Price
  • VSME N/A
  • ICUCW N/A
  • AVG Volume (30 Days)
  • VSME 121.7K
  • ICUCW N/A
  • Earning Date
  • VSME 07-22-2025
  • ICUCW N/A
  • Dividend Yield
  • VSME N/A
  • ICUCW N/A
  • EPS Growth
  • VSME N/A
  • ICUCW N/A
  • EPS
  • VSME N/A
  • ICUCW N/A
  • Revenue
  • VSME $8,248,108.00
  • ICUCW N/A
  • Revenue This Year
  • VSME N/A
  • ICUCW N/A
  • Revenue Next Year
  • VSME N/A
  • ICUCW N/A
  • P/E Ratio
  • VSME N/A
  • ICUCW N/A
  • Revenue Growth
  • VSME 3.22
  • ICUCW N/A
  • 52 Week Low
  • VSME $0.51
  • ICUCW N/A
  • 52 Week High
  • VSME $3.69
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • VSME 58.51
  • ICUCW N/A
  • Support Level
  • VSME $1.04
  • ICUCW N/A
  • Resistance Level
  • VSME $1.19
  • ICUCW N/A
  • Average True Range (ATR)
  • VSME 0.10
  • ICUCW 0.00
  • MACD
  • VSME 0.00
  • ICUCW 0.00
  • Stochastic Oscillator
  • VSME 80.85
  • ICUCW 0.00

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: